Clinical trials: Chemically-Induced Disorders
Opioid Use Disorder, Stimulant Use Disorder
Suvorexant for Opioid/Stimulant Co-use
This study will evaluate whether Suvorexant 20mg reduces drug use and craving, and improves sleep and stress among persons with co-occurring opioid use disorder and stimulant use disorder.
- Trial name
- NCT05546515
- Testing
- Suvorexant (dual orexin receptor antagonist)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Johns Hopkins University
Opioid Overdose, Drug Overdose
The Rhode Island Prescription and Illicit Drug Study
This study will test the efficacy of a novel drug-checking intervention to prevent fatal and non-fatal overdose among people who use drugs (PWUD), who are 18-65 years old at the time of enrollment.
- Trial name
- RAPIDS (NCT04372238)
- Testing
- RAPIDS Intervention, Standard OEND
- Where
- United States
- Volunteers
- 509 people, healthy volunteers welcome
- Sponsor
- Brown University
Neonatal Abstinence Syndrome
Non-Opiate Treatment After Prenatal Opiate Exposure to Prevent Postnatal Injury to the Young Brain
The long term goals of our research are to establish the best pharmacological treatment for NAS and determine how pharmacologic treatment of NAS affects long-term developmental outcomes.
- Trial name
- No-POPPY (NCT03396588)
- Testing
- Clonidine, Morphine
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Henrietta Bada
Alcohol Dependence, Alcohol Use Disorder
Extended-release Naltrexone and Care Management for Alcohol Dependent Frequent Emergency Department Users
Our primary aim is to assess the feasibility of initiating treatment in the ED with extended-release naltrexone (XR-NTX) plus care management (CM) vs.
- Trial name
- NCT02445339
- Testing
- XR-NTX+CM (Extended-Release Naltrexone plus Care Management)
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- NYU Langone Health